Purchase this article with an account.
M.-A. Economou, M. Dominici, G. Grisendi, D. Vasilcanu; Expression of Ganglioside GD2 in 4 Different Uveal Melanoma Cell Lines. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3386.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Uveal melanoma is the most common primary malignancy of the eye and results in metastatic death in up to half of the patients. Although new therapeutic modalities have been available in the last two decades, they were not able to improve the prognosis of this disease. This fact makes even more urgent the need to indentify new prognostic markers and therapeutic targets. Tumor tissues of neuroectodermal origin, such as melanoma, neuroblastoma and glioma have an increased surface membrane expression of gangliosides such as GD2.
The expression of GD2 was measured in four different uveal melanoma cell lines (OCM-1, OCM-3, OCM-8, 92-1) and one cutaneous melanoma cell line (DFB) with Fluorescence-Activated Cell Sorting (FACS) with the use of adequate antibodies while analysis was performed by using CXP software.
92-1 and OCM-1 expressed high levels of GD2 while OCM-3 and OCM-8 expressed moderate and low levels of GD2 respectively. The expression level of DFB was high as expected, since that was well known from the literature and was therefore was used as positive control.
Although these results are preliminary and further studies are necessary in order to confirm these first findings, GD2 could be considered as a potential candidate marker for uveal melanoma.
This PDF is available to Subscribers Only